Sarcoidosis News and Research

Latest Sarcoidosis News and Research

Microglia play vital role in regulating neuroinflammation, research shows

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system--including the retina of the eye--serve as "gatekeepers," or biosensors and facilitators, of neuroinflammation in a preclinical model of autoimmune uveitis.

23 Apr 2019

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.

18 Jan 2019

Yale researchers use arthritis medication to treat patient with disfiguring sarcoidosis

An all-Yale team of researchers successfully treated a patient with disfiguring sarcoidosis, a chronic disease that can affect multiple organs, with a drug approved for rheumatoid arthritis.

26 Dec 2018

Middle-aged adults with lung disease may have greater risk of dementia later in life

Middle-aged adults with lung disease may be at greater risk of developing dementia or cognitive impairment later in life, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

26 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Gram-negative bacteria found to be risk factor for worse outcomes in hospitalized ILD patients

Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases. In a study at CHEST 2018, researchers at Beaumont Health Systems studied the influence of bacterial virulence on clinical outcomes patients hospitalized with ILD patients.

4 Oct 2018

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Dr. Lesley Ann Saketkoo, an associate professor of clinical medicine at Tulane University School of Medicine, has been named Doctor of the Year by the Scleroderma Foundation. The award recognizes leadership and commitment to the community battling scleroderma, a disabling and life-limiting multi-organ autoimmune disease with progressive lung, heart, kidney, gastrointestinal tract and/or vascular involvement.

21 Aug 2018

ERS collaborates with 3D Systems to provide simulation equipment for EBUS training centers

The European Respiratory Society and 3D Systems have signed a collaboration agreement to provide simulation equipment and event services for training centers for use in the ERS Endobronchial Ultrasound Certified Training Program.

3 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Researchers create revolutionary model to study pulmonary diseases

Researchers at the University of Arizona College of Medicine - Phoenix have developed a revolutionary "lung on a leaf" to study pulmonary diseases.

21 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Improving the Diagnosis of Cardiac Sarcoidosis

Cardiac sarcoidosis is an inflammatory disease of the heart that results in various clinical manifestations. Dr Nadera Sweiss discusses her research in the field of sarcoidosis and how diet can influence the diagnosis of the condition.

30 Apr 2018

New research grant by Fisher & Paykel Healthcare to advance COPD patient care

The ATS Foundation is pleased to announce the new ATS Foundation/Fisher & Paykel Healthcare Research Award in Respiratory Support with Nasal High Flow in Patients with COPD. The award will provide funding for two years in the amount of $100,000.

29 Mar 2018

Scientists use ‘big-data’ to define burden of sarcoidosis

Physician-scientists from the University of Alabama at Birmingham using "big-data" recently summarized in the Journal of the American Heart Association the prevalence of cardiovascular manifestations, rates of defibrillator placement and predictors of in-hospital mortality in sarcoidosis -; a disorder that affects multiple organs.

7 Feb 2018

New total-body PET scanner could revolutionize patient diagnosis and care

The new total-body PET/CT scanner could revolutionize our understanding and treatment of disease through analysis of better imaging data from the whole body.

3 Jan 2018

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

Firstly, it is necessary to make a distinction between systemic inflammation and Systemic Inflammatory Response Syndrome (SIRS). SIRS consists of changes in clinical signs including an abnormal body temperature, increased heart rate, increased respiratory rate, an abnormal white cell count (either decreased or elevated), or an increase in band neutrophils.

7 Sep 2017

Sarcoidosis News and Research

Latest Sarcoidosis News and Research

Microglia play vital role in regulating neuroinflammation, research shows

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Yale researchers use arthritis medication to treat patient with disfiguring sarcoidosis

Middle-aged adults with lung disease may have greater risk of dementia later in life

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gram-negative bacteria found to be risk factor for worse outcomes in hospitalized ILD patients

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

ERS collaborates with 3D Systems to provide simulation equipment for EBUS training centers

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Researchers create revolutionary model to study pulmonary diseases

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Improving the Diagnosis of Cardiac Sarcoidosis

New research grant by Fisher & Paykel Healthcare to advance COPD patient care

Scientists use ‘big-data’ to define burden of sarcoidosis

New total-body PET scanner could revolutionize patient diagnosis and care

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sarcoidosis News and Research

Latest Sarcoidosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in